The impact of adverse reactions on adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy in Japan.

Background: Allergen immunotherapy is the only treatment that can achieve remission for allergic diseases. Aims/Objectives: To investigate the three-year adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy at a clinic in Japan and identify factors that inf...

Descripción completa

Detalles Bibliográficos
Publicado en:Acta Oto-Laryngologica Vol. 144; no. 7/8; pp. 467 - 476
Autor principal: Masuno, Satoru
Formato: research tables/charts Journal Article
Publicado: Taylor & Francis Ltd Jul/Aug2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=180230459&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 180230459
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00016489
        B6D
      jtl: Acta Oto-Laryngologica
      issn: 00016489
      maglogo: Y
    pubinfo:
      dt: Jul/Aug2024
      vid: 144
      iid: 7/8
      pid: 377
      pub: Taylor & Francis Ltd
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        180230459
        179587582
        180230459
        180230459
        10.1080/00016489.2024.2397054
        180230459
      ppf: 467
      ppct: 9
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: The impact of adverse reactions on adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy in Japan.
      aug:
        au: Masuno, Satoru
        affil: Makinohara Nanohana Otorhinolaryngology Clinic, Chiba, Japan
      sug:
        subj:
          Plants Adverse Effects
          Dust Mites
          Rhinitis, Allergic, Seasonal Drug Therapy
          Rhinitis, Allergic, Perennial Drug Therapy
          Sublingual Immunotherapy Adverse Effects
          Medication Compliance
          Human
          Japan
          Child
          Adolescence
          Adult
          Middle Age
          Aged
          Male
          Female
          Hematologic Tests
          Treatment Duration
          Descriptive Statistics
          Immunoglobulins Blood
          Child: 6-12 years
          Adolescent: 13-18 years
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Male
          Female
      ab:
        Background: Allergen immunotherapy is the only treatment that can achieve remission for allergic diseases. Aims/Objectives: To investigate the three-year adherence to sublingual immunotherapy for Japanese cedar pollinosis and house dust mite allergy at a clinic in Japan and identify factors that influence adherence and severe adverse reactions. Material and Methods: In total, 174 patients aged 12 years or older who started sublingual immunotherapy for Japanese cedar pollinosis (n = 72), house dust mite allergy (n = 55), or both (n = 47) between May 2017 and June 2018. Patient age, sex, type of pharmacotherapy used, adverse reactions, blood test results, and duration of continuous treatment were investigated. Results: The three-year treatment continuation rate was 40.8%. Adverse reaction rates were 12.6% for cedar pollinosis and 40.2% for house dust mite allergy. Patients with dose reductions due to severe reactions had lower first-year continuation rates. In the MITICURE® group, patients with severe reactions had significantly higher serum total IgE levels. Severe reactions were more common in MITICURE® patients with seven or more positive antigen types. Conclusions and Significance: Severe adverse reactions reduced early adherence.
        过敏原免疫疗法是唯一可以缓解过敏性疾病的治疗方法。 调查日本一家诊所对日本柳杉花粉病和居室尘螨过敏的舌下免疫疗法的三年持续性, 并确定影响持续性和严重不良反应的因素。 2017 年 5 月至 2018 年 6 月期间, 共有 174 名 12 岁或以上的患者开始接受舌下免疫疗法来治疗日本柳杉花粉病(n = 72)、居室尘螨过敏(n = 55)或两者兼有的病症(n = 47)。调查了患者的年龄、性别、所用药物治疗类型、不良反应、血液检查结果和持续治疗时间。 三年治疗持续率为 40.8%。柳杉花粉病的不良反应率为 12.6%, 居室尘螨过敏的不良反应率为 40.2%。因严重反应而减少剂量的患者第一年继续用药率较低。在 MITICURE® 组中, 发生严重反应的患者血清总 IgE 水平明显较高。严重反应在具有七种或更多种阳性抗原类型的 MITICURE® 患者中更为常见。 严重不良反应会降低早期持续性。
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N